SCHEMBL15041569

SCHEMBL15041569

Cc1scnc1C#Cc1cc2cnc(Nc3ccc(OC4CCCN(C)C4)cc3)nc2n(Cc2cncn2-c2ccccc2)c1=O

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 2/20 0.35
CDK4 P11802 2/20 0.35
CCNA2 P20248 2/20 0.35
CCND1 P24385 2/20 0.35
CDK2 P24941 2/20 0.35
PIK3CD O00329 1/20 0.35
PRKAB2 O43741 1/20 0.35
NUAK1 O60285 1/20 0.35
CCNT1 O60563 1/20 0.35
ABL1 P00519 1/20 0.35
FYN P06241 1/20 0.35
CDK1 P06493 1/20 0.35
CSF1R P07333 1/20 0.35
RET P07949 1/20 0.35
PDGFRB P09619 1/20 0.35
CCNB1 P14635 1/20 0.35
CCNE1 P24864 1/20 0.35
MARK3 P27448 1/20 0.35
FLT3 P36888 1/20 0.35
CDK7 P50613 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15036264 0.88 FGFR1 (0.35) FGFR1CDK4CCNA2CCND1CDK2
SCHEMBL15617474 0.80 CAMK2D (0.40) FGFR1CDK4CCNA2CCND1CDK2
SCHEMBL15036474 0.79 PIK3CD (0.37) FGFR1CDK4CCNA2CCND1CDK2
SCHEMBL15041731 0.78 CCND1 (0.40) FGFR1CDK4CCNA2CCND1CDK2
SCHEMBL15258241 0.78 MAP4K1 (0.41) FGFR1CDK4CCNA2CCND1CDK2
SCHEMBL15041509 0.77 CAMK2D (0.39) FGFR1CDK4CCNA2CCND1CDK2
SCHEMBL15034970 0.76 TNK2 (0.48) TNK2SRCRIPK2ACVR1NOD2
SCHEMBL15041729 0.75 CDK4 (0.46) FGFR1CDK4CCNA2CCND1CDK2
SCHEMBL15041895 0.74 FGFR1 (0.36) FGFR1CDK4CCNA2CCND1CDK2
SCHEMBL15041728 0.74 RIPK2 (0.36) CDK4CCNA2CCND1CDK2FLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8680099-B2 6-(ethynyl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders AFRAXIS HOLDINGS, INC. (US) 2014-03-25 US disclosed
US-8680099-B2 6-(ethynyl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders AFRAXIS HOLDINGS, INC. (US) 2014-03-25 US disclosed
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER AFRAXIS, INC. (US) 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER PAK5, PAK2, PAK6 FGFR1 1919/4885CDK4 404/4885CCNA2 2011/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.